Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson May 30, 2023 12:39pm

194 Views

Post# 35470527

ASCO pre-release effect

A biotechs have release extracts, pending full results later at ASCO.

All got crushed by the market and then SP bump back up a bit.

This strategy of releasing piecemeal results is just confusing the market and annoying shareholders. Adding another complexity to the matter.

Next time, just shut up and wow us.

Anyhow, because there are two stastiscal trial done - one can say that endpoint will be meet with a very level of certainty.
In other word, should ONCY replicate IND-213+Bracelet, the odds of success are in between 95 to 99%. I will let the math nerd publish their calculation here.

So, PIII appears to be cheap (2 arm) and almost a certainty if you include biomarker reading.
The market should be rewarding us a full 2$, imo just for this.

But but but, this half lingerie tactic is confusing the market.
Either you show up in full lingerie or you stay cover...